Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.28 Analyst target: $68.00 Upside: 5212.50%
Skye Bioscience, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes therapeutic drugs that modulate the endocannabinoid system. The company is headquartered in San Diego, California.
See the full interactive analysis & chart →Informational only — not investment advice.